JP2005516041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516041A5 JP2005516041A5 JP2003563287A JP2003563287A JP2005516041A5 JP 2005516041 A5 JP2005516041 A5 JP 2005516041A5 JP 2003563287 A JP2003563287 A JP 2003563287A JP 2003563287 A JP2003563287 A JP 2003563287A JP 2005516041 A5 JP2005516041 A5 JP 2005516041A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- omega interferon
- administered
- warm
- blooded animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 claims 20
- 108010050904 Interferons Proteins 0.000 claims 20
- 229940079322 interferon Drugs 0.000 claims 20
- 241001465754 Metazoa Species 0.000 claims 11
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 2
- 229960000951 mycophenolic acid Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- PJFQWSNOXLEDDZ-MGPUTAFESA-N [(2r)-1-cyanobutan-2-yl] n-[(1s)-1-[3-[(4-cyano-3-methoxyphenyl)carbamoylamino]phenyl]ethyl]carbamate Chemical compound N#CC[C@@H](CC)OC(=O)N[C@@H](C)C1=CC=CC(NC(=O)NC=2C=C(OC)C(C#N)=CC=2)=C1 PJFQWSNOXLEDDZ-MGPUTAFESA-N 0.000 claims 1
- GYCPCOJTCINIFZ-JXFKEZNVSA-N [(2s)-1-cyanobutan-2-yl] n-[(1s)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate Chemical compound N#CC[C@H](CC)OC(=O)N[C@@H](C)C1=CC=CC(NC(=O)NC=2C=C(OC)C(C=3OC=NC=3)=CC=2)=C1 GYCPCOJTCINIFZ-JXFKEZNVSA-N 0.000 claims 1
- JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33794801P | 2001-11-09 | 2001-11-09 | |
| PCT/US2002/036025 WO2003063573A2 (en) | 2001-11-09 | 2002-11-08 | Method for treating diseases with omega interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516041A JP2005516041A (ja) | 2005-06-02 |
| JP2005516041A5 true JP2005516041A5 (enExample) | 2007-12-27 |
Family
ID=27662937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003563287A Pending JP2005516041A (ja) | 2001-11-09 | 2002-11-08 | オメガインターフェロンを用いる疾患の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20030143197A1 (enExample) |
| EP (1) | EP1536839B1 (enExample) |
| JP (1) | JP2005516041A (enExample) |
| KR (1) | KR20040053291A (enExample) |
| CN (1) | CN100438870C (enExample) |
| AT (1) | ATE481135T1 (enExample) |
| AU (1) | AU2002365436B8 (enExample) |
| CA (1) | CA2466228A1 (enExample) |
| DE (1) | DE60237721D1 (enExample) |
| IL (2) | IL161889A0 (enExample) |
| NZ (1) | NZ532779A (enExample) |
| WO (1) | WO2003063573A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| OA12835A (fr) * | 2003-10-29 | 2006-09-15 | Koung Nee Bellet Anne Brigitte Dr | Interferon omega contre le VIH/SIDA, le cancer et asthme humain et veterinaire. |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| DE602007009377D1 (de) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
| EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| NO2462246T3 (enExample) | 2009-09-28 | 2018-02-03 | ||
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| TWI754643B (zh) | 2016-05-16 | 2022-02-11 | 美商因塔希亞治療公司 | 升糖素受體選擇性多肽和彼之使用方法 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| WO2018129058A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| CN111973600B (zh) * | 2020-08-20 | 2021-11-16 | 华中农业大学 | 霉酚酸或其衍生物在制备犬瘟热病毒抑制剂中的用途 |
| WO2024015586A1 (en) * | 2022-07-15 | 2024-01-18 | Whitehead Institute For Biomedical Research | Compositions and methods for treating cancer with interferon-omega and analogs thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3273597D1 (en) * | 1981-11-28 | 1986-11-06 | Sunstar Kk | Pharmaceutical composition containing interferon in stable state |
| US5004689A (en) * | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| DE3220116A1 (de) * | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
| US5120832A (en) * | 1984-08-27 | 1992-06-09 | Genentech, Inc. | Distinct family of human leukocyte interferons |
| US5231176A (en) * | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| FI90990C (fi) * | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| US4885166A (en) * | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
| US4845196A (en) * | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
| US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
| DE3607835A1 (de) * | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
| ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
| CA1320905C (en) * | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| DE3642096A1 (de) * | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
| US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
| US4917895A (en) * | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
| US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
| US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
| US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
| US5223266A (en) * | 1990-01-24 | 1993-06-29 | Alza Corporation | Long-term delivery device with early startup |
| US5120306A (en) * | 1990-03-21 | 1992-06-09 | Gosselin Leon F | Direct delivery of anti-inflammatories to the proximal small bowel |
| US5207752A (en) * | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
| US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| MX9200038A (es) * | 1991-01-09 | 1992-11-01 | Alza Corp | Dispositivos biodegradables y composiciones para la liberacion por difusion de agentes. |
| US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
| FR2690622B1 (fr) * | 1992-04-29 | 1995-01-20 | Chronotec | Système de pompe à perfusion ambulatoire programmable. |
| US5805688A (en) * | 1993-04-01 | 1998-09-08 | U.S. West Advanced Technologies, Inc. | Automated system and method for call handling |
| PT741577E (pt) * | 1994-03-07 | 2003-03-31 | Imperial College | Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado |
| US5939286A (en) * | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
| US6129761A (en) * | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| WO1997027840A1 (en) * | 1996-02-02 | 1997-08-07 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| EP0904373A1 (en) * | 1996-03-14 | 1999-03-31 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| US6204022B1 (en) * | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
| US6180131B1 (en) * | 1997-04-07 | 2001-01-30 | The Iams Company | Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| AR013256A1 (es) * | 1997-12-30 | 2000-12-13 | Intarcia Therapeutics Inc | DISPOSICIoN DE ADMINISTRACIoN PARA UNA ADMINISTRACIoN CONTROLADA DE UN AGENTE BENÉFICO, MÉTODO PARA FORMAR UNA DISPOSICIoN DE ADMINISTRACIoN , MÉTODO PARA HACER UNA DISPOSICIoN DE ADMINISTRACIoN Y MÉTODO DE CONTROLAR UNA VELOCIDAD DE LIBERACIoN. |
| CN1230198C (zh) * | 1998-05-15 | 2005-12-07 | 先灵公司 | 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法 |
| TW586944B (en) * | 1998-05-29 | 2004-05-11 | Sumitomo Pharma | Controlled release agent having a multi-layer structure |
| US7390637B2 (en) * | 1998-07-21 | 2008-06-24 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| US6472512B1 (en) * | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| WO2000040273A2 (en) * | 1999-01-08 | 2000-07-13 | Vical Incorporated | Treatment of viral diseases using an interferon omega expressing polynucleotide |
| US6833256B1 (en) * | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
| US6436091B1 (en) * | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| EP1278551A2 (en) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| EP1450836A4 (en) * | 2000-11-03 | 2007-07-25 | Intarcia Therapeutics Inc | PROCESS FOR SHORT AND LONG-TERM DOSAGE OF MEDICAMENTS |
-
2002
- 2002-11-08 KR KR10-2004-7007037A patent/KR20040053291A/ko not_active Ceased
- 2002-11-08 US US10/290,790 patent/US20030143197A1/en not_active Abandoned
- 2002-11-08 EP EP02805705A patent/EP1536839B1/en not_active Expired - Lifetime
- 2002-11-08 JP JP2003563287A patent/JP2005516041A/ja active Pending
- 2002-11-08 AT AT02805705T patent/ATE481135T1/de active
- 2002-11-08 CA CA002466228A patent/CA2466228A1/en not_active Abandoned
- 2002-11-08 AU AU2002365436A patent/AU2002365436B8/en not_active Ceased
- 2002-11-08 DE DE60237721T patent/DE60237721D1/de not_active Expired - Lifetime
- 2002-11-08 NZ NZ532779A patent/NZ532779A/en not_active IP Right Cessation
- 2002-11-08 IL IL16188902A patent/IL161889A0/xx unknown
- 2002-11-08 CN CNB028245261A patent/CN100438870C/zh not_active Expired - Fee Related
- 2002-11-08 WO PCT/US2002/036025 patent/WO2003063573A2/en not_active Ceased
-
2004
- 2004-05-09 IL IL161889A patent/IL161889A/en not_active IP Right Cessation
-
2007
- 2007-06-07 US US11/811,415 patent/US20070248572A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516041A5 (enExample) | ||
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| JP2002515453A5 (enExample) | ||
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| DE60131250T8 (de) | Nucleosid-analoga mit monozyklischen basischen carboxamidingruppen | |
| JP2013522302A5 (enExample) | ||
| CA2245938A1 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| SK155997A3 (en) | Use of ribavirin and interferon alpha for the treatment of hepatitis c | |
| JP2007522237A5 (enExample) | ||
| RU2006115916A (ru) | Комбинированная терапия hcv инфекции | |
| Manns et al. | Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1 | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| WO1999018993A1 (en) | Ameliorant for hepatitis c remedial effect and application thereof | |
| JPWO1999018993A1 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| TWI524895B (zh) | Ｃ型肝炎病毒感染之新治療方法 | |
| Creutzig et al. | Severe Raynaud's syndrome associated with interferon therapy: a case history | |
| JP2001288110A5 (enExample) | ||
| Tran et al. | Chronic hepatitis C | |
| WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
| Lau | HBeAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon | |
| JP2014509628A (ja) | Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル | |
| Nozic et al. | Severe mononeuritis multiplex associated with peginterferon-ribavirin therapy of chronic hepatitis C | |
| Cacoub | Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence? | |
| JPWO2019217643A5 (enExample) |